Vistin Pharma ASA (OL:VISTN) — Stock Price
Vistin Pharma ASA (OL:VISTN) is currently trading at Nkr18.50 NOK, up 1.37% today. Over the past 52 weeks, shares have ranged between Nkr18.10 and Nkr23.20. This page tracks Vistin Pharma ASA's live share price on the OL exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see VISTN stock market capitalisation.
Vistin Pharma ASA (VISTN) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Vistin Pharma ASA's daily closing share price and trading volume on the OL exchange over the past year, giving a clear view of recent price momentum and liquidity.
Vistin Pharma ASA Income Statement — Revenue, Profit & Earnings by Year
Vistin Pharma ASA's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Nkr452.29 Million | Nkr429.09 Million | Nkr435.39 Million | Nkr287.68 Million | Nkr278.62 Million |
| Cost of Revenue | Nkr220.34 Million | Nkr149.97 Million | Nkr233.15 Million | Nkr199.88 Million | Nkr96.10 Million |
| Gross Profit | Nkr231.95 Million | Nkr279.12 Million | Nkr259.69 Million | Nkr166.80 Million | Nkr182.53 Million |
| Research & Development | — | — | — | — | — |
| SG&A | Nkr18.55 Million | Nkr94.22 Million | Nkr26.10 Million | Nkr19.82 Million | Nkr73.43 Million |
| Total Operating Expenses | Nkr359.94 Million | Nkr343.80 Million | Nkr366.79 Million | Nkr293.77 Million | Nkr242.56 Million |
| Operating Income | Nkr92.35 Million | Nkr85.30 Million | Nkr68.60 Million | Nkr-6.10 Million | Nkr33.25 Million |
| EBITDA | — | — | — | Nkr8.41 Million | Nkr42.96 Million |
| EBIT | — | Nkr85.30 Million | Nkr68.60 Million | Nkr-6.10 Million | Nkr33.25 Million |
| Interest Expense | Nkr1.96 Million | Nkr2.34 Million | Nkr2.27 Million | Nkr2.14 Million | Nkr357.00K |
| Income Before Tax | Nkr95.84 Million | Nkr80.45 Million | Nkr58.52 Million | Nkr-6.01 Million | Nkr31.99 Million |
| Income Tax Expense | — | — | — | Nkr-1.32 Million | Nkr7.13 Million |
| Net Income | Nkr74.75 Million | Nkr62.75 Million | Nkr45.60 Million | Nkr-4.72 Million | Nkr24.95 Million |
Vistin Pharma ASA Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Vistin Pharma ASA's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Nkr439.43 Million | Nkr384.94 Million | Nkr403.40 Million | Nkr407.21 Million | Nkr333.15 Million |
| Total Current Assets | Nkr203.52 Million | Nkr143.19 Million | Nkr168.77 Million | Nkr154.11 Million | Nkr137.83 Million |
| Cash & Equivalents | — | — | Nkr26.20 Million | Nkr1.44 Million | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | Nkr89.71 Million | Nkr44.28 Million | Nkr47.02 Million | Nkr66.16 Million | Nkr40.24 Million |
| Inventory | Nkr82.13 Million | Nkr76.67 Million | Nkr80.17 Million | Nkr83.45 Million | Nkr42.91 Million |
| Property, Plant & Equipment | — | — | Nkr219.98 Million | Nkr219.47 Million | Nkr167.46 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Nkr110.62 Million | Nkr75.42 Million | Nkr80.63 Million | Nkr133.95 Million | Nkr57.26 Million |
| Total Current Liabilities | Nkr86.72 Million | Nkr63.97 Million | Nkr69.47 Million | Nkr111.67 Million | Nkr41.03 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | Nkr43.71 Million | — |
| Total Stockholder Equity | Nkr328.81 Million | Nkr309.53 Million | Nkr322.77 Million | Nkr273.26 Million | Nkr275.89 Million |
| Retained Earnings | Nkr210.60 Million | Nkr135.89 Million | Nkr71.54 Million | Nkr22.14 Million | Nkr24.54 Million |
Vistin Pharma ASA Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Vistin Pharma ASA generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Nkr78.04 Million | Nkr107.86 Million | Nkr90.59 Million | Nkr-8.87 Million | Nkr13.68 Million |
| Capital Expenditures | Nkr16.68 Million | Nkr40.80 Million | Nkr17.90 Million | Nkr64.29 Million | Nkr31.94 Million |
| Free Cash Flow | Nkr61.35 Million | Nkr67.05 Million | Nkr72.69 Million | Nkr-74.80 Million | Nkr-18.26 Million |
| Investing Cash Flow | — | Nkr-40.30 Million | Nkr-17.68 Million | Nkr-64.29 Million | Nkr-31.68 Million |
| Financing Cash Flow | — | Nkr-80.97 Million | Nkr-48.14 Million | Nkr38.85 Million | Nkr-23.30 Million |
| Dividends Paid | Nkr-55.43 Million | Nkr77.59 Million | Nkr0.00 | Nkr0.00 | Nkr22.17 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Nkr22.53 Million | Nkr19.03 Million | Nkr17.35 Million | Nkr12.28 Million | Nkr10.61 Million |
| Change in Cash | Nkr3.62 Million | Nkr-13.41 Million | Nkr24.77 Million | Nkr-34.31 Million | Nkr-41.29 Million |
Vistin Pharma ASA Earnings History — EPS Actual vs. Analyst Estimates
Track Vistin Pharma ASA's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 20, 2026 | — | — | — |
| Apr 24, 2026 | 0.48 | — | — |
| Dec 31, 2025 | 0.36 | — | — |
| Oct 31, 2025 | 0.42 | — | — |
| Jun 30, 2025 | 0.42 | — | — |
| Apr 25, 2025 | 0.49 | — | — |
| Feb 14, 2025 | 0.44 | — | — |
| Oct 31, 2024 | 0.37 | — | — |